Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | N/A | N/A | Up |
| Historical ZNTL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -1.01% | |
| Multiple of Ten Bullish | Other | -1.01% | |
| Outside Day | Range Expansion | -1.01% | |
| Wide Bands | Range Expansion | -1.01% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 4.19% | |
| Narrow Range Bar | Range Contraction | 4.19% | |
| NR7 | Range Contraction | 4.19% | |
| Multiple of Ten Bearish | Other | 4.19% | |
| Inside Day | Range Contraction | 4.19% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Biopharmaceutical Cancer Drugs Hormones Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2/Neu Metastatic Breast Cancer Antiestrogens Selective Estrogen Receptor Degraders
Biopharmaceutical Cancer Drugs Hormones Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2/Neu Metastatic Breast Cancer Antiestrogens Selective Estrogen Receptor Degraders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.6099 |
| 52 Week Low | 23.25 |
| Average Volume | 187,069 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 36.87 |
| 10-Day Moving Average | 40.10 |
| Average True Range | 3.76 |
| ADX | 52.26 |
| +DI | 30.55 |
| -DI | 6.65 |
| Chandelier Exit (Long, 3 ATRs ) | 37.33 |
| Chandelier Exit (Short, 3 ATRs ) | 39.29 |
| Upper Bollinger Band | 44.42 |
| Lower Bollinger Band | 29.31 |
| Percent B (%b) | 0.79 |
| BandWidth | 40.99 |
| MACD Line | 3.65 |
| MACD Signal Line | 3.66 |
| MACD Histogram | -0.0065 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.86 | ||||
| Resistance 3 (R3) | 45.06 | 44.08 | 44.27 | ||
| Resistance 2 (R2) | 44.08 | 43.17 | 43.98 | 44.07 | |
| Resistance 1 (R1) | 42.69 | 42.61 | 42.20 | 42.49 | 43.87 |
| Pivot Point | 41.70 | 41.70 | 41.46 | 41.60 | 41.70 |
| Support 1 (S1) | 40.31 | 40.79 | 39.82 | 40.11 | 38.73 |
| Support 2 (S2) | 39.33 | 40.23 | 39.23 | 38.53 | |
| Support 3 (S3) | 37.94 | 39.33 | 38.33 | ||
| Support 4 (S4) | 37.74 |
